BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote in favor of the juice that you love for its medical advantages! - 2Obamacare enrollment declines as US subsidies expire
- 3Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- 4Independence from the rat race: How to Save and Contribute Shrewdly
- 5This Tiny Neon Frog Dwells in the Clouds
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- Russia Creates New Military Branch Dedicated To Drone Warfare
- Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
- Pick Your #1 Kind Of Bread
- You finally got a doctor's appointment. Here's how to get the most out of it
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- An Extended time of Self-Reflection: Self-awareness through Journaling
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- 25 of the world’s best sandwiches
